Patents by Inventor Margaretha Olthoff
Margaretha Olthoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11160793Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: GrantFiled: October 12, 2016Date of Patent: November 2, 2021Assignee: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
-
Patent number: 10993933Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.Type: GrantFiled: June 29, 2015Date of Patent: May 4, 2021Assignee: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Patent number: 10543196Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.Type: GrantFiled: June 6, 2016Date of Patent: January 28, 2020Assignee: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20170100376Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: ApplicationFiled: October 12, 2016Publication date: April 13, 2017Applicant: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Quatas, Margaretha Olthoff
-
Publication number: 20170095452Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.Type: ApplicationFiled: June 6, 2016Publication date: April 6, 2017Inventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20160106716Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: ApplicationFiled: May 20, 2015Publication date: April 21, 2016Applicant: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
-
Publication number: 20150374670Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.Type: ApplicationFiled: June 29, 2015Publication date: December 31, 2015Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20150335588Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.Type: ApplicationFiled: April 24, 2015Publication date: November 26, 2015Inventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20140004190Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: ApplicationFiled: June 13, 2013Publication date: January 2, 2014Applicant: Astellas Deutschland GmbHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
-
Publication number: 20130202693Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic hydrophilic surfactant.Type: ApplicationFiled: June 1, 2011Publication date: August 8, 2013Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20120003305Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.Type: ApplicationFiled: December 3, 2009Publication date: January 5, 2012Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20120003309Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: ApplicationFiled: December 3, 2009Publication date: January 5, 2012Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
-
Patent number: 5085869Abstract: A wet granulate is provided for therapeutically useful substances having a water solubility 10 wt % or less and microcrystalline or microfine cellulose or a mixture of both, where substantial amounts of wet binders are avoided.Tableting mixtures with the new granulate possess a good flow pattern and may be compressed to tablets which show an excellent disintegration behavior.Type: GrantFiled: February 24, 1989Date of Patent: February 4, 1992Assignee: Gist-Brocades N.V.Inventors: Margaretha Olthoff, Bernardus L. J. Dijkgraaf, Piet J. Akkerboom
-
Patent number: 4950484Abstract: A pharmaceutical tablet containing an amphoteric beta-lactam antibiotic, microcrystalline or micro fine cellulose or a mixture of both and a second disintegrant, being low-substituted hydroxypropylcellulose, which fully disintegrates in water within 60 seconds. When swallowed it shows a bioavailability as good as a pharmacy prepared suspension of the antibiotic. The tablet is compressed from a mixture containing a new granulate which is prepared from the antibiotic substance, microcrystalline and/or micro fine cellulose and water only. Such tablets can also be prepared by using other known tablet disintegrants as the second disintegrant.Type: GrantFiled: March 2, 1988Date of Patent: August 21, 1990Assignee: Gist-Brocades N.V.Inventors: Margaretha Olthoff, Leonardus W. T. De Boer, Piet J. Akkerboom